文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

酒精相关肝病患者的酒精使用障碍治疗：创新方法和行动呼吁。

Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action.

机构信息

Department of Medicine, Digestive Diseases, & Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Department of Internal Medicine, Addiction Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916, Badalona (Barcelona), Spain.

出版信息

Addict Sci Clin Pract. 2024 Mar 19;19(1):19. doi: 10.1186/s13722-024-00448-8.

DOI:10.1186/s13722-024-00448-8
PMID:38504384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10949674/
Abstract

Alcohol-associated liver disease is currently the leading cause of liver transplantation and liver deaths both in Europe and the United States. Efficacious treatments exist for alcohol use disorder, but they are seldomly prescribed for patients who need them. Besides, the presence of liver cirrhosis can complicate pharmacological treatment choices. In this review, we discuss established and innovative treatment strategies to treat unhealthy alcohol use in patients with alcohol-associated liver disease. We also describe the experience of our own institutions, Hospital Universitari Germans Trias i Pujol in Badalona (Spain) and Yale-New Haven Health and Yale Medicine (Connecticut. United States of America).

摘要

酒精相关性肝病目前是欧洲和美国肝移植和肝死亡的主要原因。对于酒精使用障碍，存在有效的治疗方法，但很少为需要的患者开这些药物。此外，肝硬化的存在会使药物治疗的选择变得复杂。在这篇综述中，我们讨论了用于治疗酒精相关性肝病患者不健康饮酒的既定和创新治疗策略。我们还描述了我们自己的机构的经验，西班牙巴达洛纳的 Germans Trias i Pujol 大学医院和美国康涅狄格州耶鲁-纽黑文健康和耶鲁大学医学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5899/10949674/5fb35a6cb84e/13722_2024_448_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5899/10949674/5fb35a6cb84e/13722_2024_448_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5899/10949674/5fb35a6cb84e/13722_2024_448_Fig1_HTML.jpg

相似文献

[1]
Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action.

Addict Sci Clin Pract. 2024-3-19

[2]
Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.

Clin Ther. 2023-12

[3]
Covid-19 and alcohol associated liver disease.

Dig Liver Dis. 2022-11

[4]
Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy.

Semin Liver Dis. 2022-5

[5]
Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder.

Clin Gastroenterol Hepatol. 2023-7

[6]
Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence.

World J Gastroenterol. 2015-7-28

[7]
Multidisciplinary Care of Alcohol-related Liver Disease and Alcohol Use Disorder: A Narrative Review for Hepatology and Addiction Clinicians.

Clin Ther. 2023-12

[8]
Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.

Am J Med. 2017-2

[9]
Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.

Hepatology. 2020-9

[10]
Diagnosis and Treatment of Alcohol Use Disorder in Patients With End-Stage Alcoholic Liver Disease.

Hepatology. 2019-1-17

引用本文的文献

[1]
Culturally tailored steatotic liver disease management: Latino and Asian community partner perspectives and recommendations.

Hepatol Commun. 2025-6-9

[2]
Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis.

Alcohol Clin Exp Res (Hoboken). 2025-1

[3]
Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease.

Aliment Pharmacol Ther. 2025-2

[4]
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on "The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study".

Clin Mol Hepatol. 2025-1

[5]
Real-world analysis on the use of gamma-hydroxybutyric acid for alcohol withdrawal syndrome in hospitalized patients with diagnosis of cirrhosis.

Intern Emerg Med. 2025-1

本文引用的文献

[1]
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

Hepatology. 2023-5-1

[2]
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease.

Hepatol Commun. 2022-12

[3]
Psychotherapy for Alcohol Use Disorder Is Associated With Reduced Risk of Incident Alcohol-Associated Liver Disease.

Clin Gastroenterol Hepatol. 2023-6

[4]
Integrated Care of Alcohol-Related Liver Disease.

J Clin Exp Hepatol. 2022

[5]
Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.

J Addict Med.

[6]
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.

JAMA Netw Open. 2022-5-2

[7]
The stigma of alcohol-related liver disease and its impact on healthcare.

J Hepatol. 2022-8

[8]
Creation of an Inpatient Alcohol Liver Service Improves Early Liver Disease Detection in Patients With Alcohol Use Disorder.

Clin Gastroenterol Hepatol. 2023-6

[9]
Alcohol-Associated Liver Disease Mortality Increased From 2017 to 2020 and Accelerated During the COVID-19 Pandemic.

Clin Gastroenterol Hepatol. 2022-9

[10]
OPTN/SRTR 2020 Annual Data Report: Liver.

Am J Transplant. 2022-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索